Brief Report: Clinical outcomes of metastatic non-small cell lung cancer patients after discontinuation of immunotherapy due to immune-related adverse effects

Open AccessPublished:November 24, 2022DOI:
      This paper is only available as a PDF. To read, Please Download here.



      Immune checkpoint inhibition (ICI) is an important treatment modality in metastatic non-small cell lung cancer (NSCLC) and management of immunotherapy related adverse effects (irAEs) can be challenging. Retreatment after discontinuation of ICI due to irAEs is a frequent clinical dilemma with limited available data.


      This single-center retrospective observational study reviewed the clinical course of 30 metastatic NSCLC patients in whom ICI had to be discontinued due to a serious irAE after an initial objective response to therapy.


      After ICI discontinuation, 14 patients (47%) developed a durable response of more than six months, 7 patients (23%) developed oligoprogression treated with local radiotherapy leading to disease control, 6 patients (20%) had progression of disease within 6 months and 3 (10%) patients died due to a severe irAE.


      A watchful waiting approach is justified after discontinuation of ICI due to irAEs in metastatic NSCLC patients with an initial response to therapy.

      Key words